These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 2495177

  • 1. Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.
    Hines DL.
    Cancer Immunol Immunother; 1989; 28(4):241-7. PubMed ID: 2495177
    [Abstract] [Full Text] [Related]

  • 2. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors.
    Dye ES, North RJ.
    J Leukoc Biol; 1984 Jul; 36(1):27-37. PubMed ID: 6234371
    [Abstract] [Full Text] [Related]

  • 3. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.
    Dye ES.
    J Immunol; 1986 Feb 15; 136(4):1510-5. PubMed ID: 3080526
    [Abstract] [Full Text] [Related]

  • 4. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.
    Carayanniotis G, Halloran PF.
    Cell Immunol; 1985 Mar 15; 91(1):100-10. PubMed ID: 2857596
    [Abstract] [Full Text] [Related]

  • 5. Progressive growth of immunogenic tumors: relationship between susceptibility of ascites P815 tumor cells to T-cell-mediated lysis and immune destruction in vivo.
    Fahey JR, Hines DL.
    Cancer Res; 1987 Sep 15; 47(18):4759-65. PubMed ID: 3113723
    [Abstract] [Full Text] [Related]

  • 6. Targeting an anti-viral CD8+ T cell response to a growing tumor facilitates its rejection.
    Böhm W, Schirmbeck R, Reimann J.
    Cancer Immunol Immunother; 1997 Jun 15; 44(4):230-8. PubMed ID: 9222282
    [Abstract] [Full Text] [Related]

  • 7. Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide.
    Inge TH, Hoover SK, Frank JL, Kawabata TT, Bethke KP, Bear HD.
    Cancer Immunol Immunother; 1992 Jun 15; 35(2):119-26. PubMed ID: 1534514
    [Abstract] [Full Text] [Related]

  • 8. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma.
    Prell RA, Kerkvliet NI.
    J Immunol; 1997 Mar 15; 158(6):2695-703. PubMed ID: 9058803
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells.
    Mills CD, North RJ.
    J Exp Med; 1983 May 01; 157(5):1448-60. PubMed ID: 6189937
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes.
    Nagy E, Baral E, Kangas L, Berczi I.
    Anticancer Res; 1997 May 01; 17(2A):1083-8. PubMed ID: 9137453
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
    Frassanito MA, Mayordomo JI, DeLeo RM, Storkus WJ, Lotze MT, DeLeo AB.
    Cancer Res; 1995 Jan 01; 55(1):124-8. PubMed ID: 7528638
    [Abstract] [Full Text] [Related]

  • 19. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.
    Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M.
    J Exp Med; 1980 Nov 01; 152(5):1184-93. PubMed ID: 6776227
    [Abstract] [Full Text] [Related]

  • 20. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
    Bear HD.
    Cancer Res; 1986 Apr 01; 46(4 Pt 1):1805-12. PubMed ID: 2936451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.